viruslik
particl
vlp
spontan
selfassembl
viral
structur
protein
appropri
condit
vitro
exclud
genet
materi
potenti
replic
probabl
addit
vlp
possess
sever
featur
includ
rapidli
produc
larg
quantiti
exist
express
system
highli
resembl
nativ
virus
term
conform
appear
display
repeat
cluster
epitop
capsid
modifi
via
genet
insert
chemic
conjug
facilit
multival
display
homolog
heterogen
epitop
antigen
therefor
vlp
consid
safe
effect
candid
prophylact
therapeut
vaccin
vlp
diamet
approxim
nm
also
characterist
nanomet
materi
larg
surfac
area
surfaceaccess
amino
acid
reactiv
moieti
eg
lysin
glutam
acid
residu
inerrat
spatial
structur
good
biocompat
therefor
assembl
vlp
great
potenti
deliveri
system
specif
carri
varieti
materi
review
summar
recent
research
vlp
develop
vaccin
biolog
vehicl
demonstr
advantag
potenti
vlp
diseas
control
prevent
diagnosi
prospect
vlp
biolog
applic
futur
discuss
well
viruslik
particl
vlp
compos
one
structur
proteinscapsid
protein
virus
selfassembl
particular
spatial
conform
term
appear
vlp
similar
live
viru
without
genet
compon
chroboczek
et
al
kushnir
et
al
high
densiti
epitop
surfac
recogn
present
immun
system
antigenpres
cell
apc
thu
stimul
humor
cellular
immun
effect
similar
pathway
origin
pathogen
time
none
viral
genet
materi
particip
format
process
vlp
mean
risk
viral
replic
prolifer
therefor
vlp
consid
one
safest
candid
vaccin
empti
viral
particl
without
nucleic
acid
identifi
capsid
protein
hepat
b
viru
blumberg
et
al
find
consid
first
record
instanc
natur
exist
vlp
subsequ
hepat
b
viru
vlp
detect
induc
host
immun
respons
elimin
invas
authent
hepat
viru
bayer
et
al
phenomenon
clue
understand
relationship
vlp
host
immun
system
progress
genet
engin
technolog
express
purif
major
capsid
protein
human
papillomaviru
hpv
achiev
easili
vitro
experi
hagense
et
al
kirnbauer
et
al
li
et
al
thu
model
understand
assembl
vlp
vitro
obtain
bradi
consigli
li
et
al
antigen
immunogen
mechan
hbsag
vlp
interpret
henc
vlpbase
vaccin
gain
attent
research
edman
et
al
mcaleer
et
al
valenzuela
et
al
applic
vlp
vaccin
one
major
biolog
applic
nanoscal
materi
vlp
similar
characterist
nanomateri
abil
mediat
biomed
function
biotechnolog
method
therefor
vlp
new
biolog
tool
signific
function
drug
deliveri
genet
therapi
cellular
target
cancer
treatment
articl
discuss
research
develop
vlp
biomed
applic
use
vaccin
one
effect
strategi
prevent
pathogen
infect
sinc
smallpox
vaccin
perform
edward
jenner
eighteenth
centuri
birth
concept
vaccin
variou
inactiv
attenu
vaccin
human
anim
emerg
fight
infecti
diseas
vaccin
made
signific
contribut
particularli
prevent
elimin
polioviru
measl
mump
rubella
influenza
hepat
amanna
slifka
lua
et
al
plotkin
howev
sever
defici
still
exist
use
inactiv
attenu
vaccin
exampl
secur
issu
attenu
vaccin
may
enhanc
pathogen
revert
wildtyp
phenotyp
vaccin
individu
although
effect
immun
respons
induc
vaccin
burn
et
al
estev
faching
et
al
horaud
sander
et
al
wang
et
al
inactiv
vaccin
replic
vivo
inocul
howev
acquir
full
protect
singl
immun
vaccin
difficult
bright
et
al
addit
urgent
practic
need
find
candid
vaccin
could
produc
effici
scalabl
inexpens
way
high
degre
safeti
virus
difficult
cultur
vitro
chackerian
moon
et
al
howev
vlp
mimick
organ
conform
authent
nativ
virus
lack
viral
genom
use
immunogen
molecul
sever
recombin
vaccin
last
year
even
use
therapeut
vaccin
induc
product
specif
antibodi
endogen
molecul
preponder
role
chronic
diseas
andrad
et
al
roldao
et
al
speiser
et
al
spohn
et
al
vlp
vaccin
licens
commerci
larg
number
vlpbase
vaccin
candid
also
undergo
clinic
evalu
see
tabl
therefor
vlp
provid
deliveri
system
combin
good
safeti
profil
strong
immunogen
constitut
safe
altern
inactiv
vaccin
attenu
vaccin
novel
type
vaccin
vlp
offer
solut
problem
primarili
biolog
properti
first
vlp
high
level
safeti
without
concern
biosecur
sinc
viral
genet
compon
introduc
product
second
vlp
present
conform
epitop
arrang
repeatedli
surfac
arrang
vlp
similar
nativ
viru
thu
vlp
easili
induc
strong
b
cell
respons
absenc
adjuv
ramqvist
et
al
third
vlp
vaccin
rapidli
cope
epidem
viral
diseas
short
time
requir
proceed
design
express
exampl
develop
prepar
vlp
vaccin
week
outbreak
influenza
month
attenu
vaccin
cox
final
vlp
pathogenassoci
molecular
pattern
pamp
recogn
pattern
recognit
receptor
prr
tolllik
receptor
tlr
host
cell
captur
antigenpres
cell
eg
dendrit
cell
fakruddin
et
al
taken
process
via
mhc
class
pathway
crosspresent
activ
cell
essenti
clearanc
intracellular
pathogen
virus
addit
vlp
inher
suitabl
size
vlp
also
taken
dendrit
cell
dc
exogen
antigen
process
present
mhc
class
ii
directli
promot
dc
matur
migrat
essenti
stimul
innat
immun
respons
whose
stimul
immun
pattern
similar
origin
viru
grgacic
anderson
keller
et
al
ponterio
et
al
raghunandan
fig
way
vlp
may
advantag
cognat
live
virus
immun
activ
virus
replic
dc
known
block
activ
matur
cell
express
particular
viral
protein
vlp
resembl
infecti
virus
retain
receptor
bind
region
abl
taken
antigenpres
cell
class
present
system
advanc
molecular
biolog
improv
express
system
vlpbase
vaccin
number
report
newli
obtain
vlp
grown
proport
system
develop
express
particl
vlp
success
use
vaccin
platform
addit
compon
viru
viru
pathogen
attach
insert
shown
stimul
cellular
humor
immun
matter
much
capsid
protein
vlp
compos
fig
advantag
safe
product
process
short
product
time
mani
avail
express
system
numer
vlp
shown
studi
vlp
use
ideal
carrier
platform
foreign
b
cell
andor
cell
epitop
display
practic
antigen
highli
immunogen
multival
format
vaccin
experi
addit
viral
epitop
rel
conserv
epitop
gene
obtain
genet
engin
subclon
plasmid
vector
thereaft
gene
genet
incorpor
gene
sequenc
coatcapsid
protein
vlp
vlp
present
exogen
antigen
fusion
express
arora
et
al
kawano
et
al
kawano
et
al
tyler
et
al
ye
et
al
simpler
mean
produc
chimer
vaccin
achiev
genet
insert
rather
chemic
link
peptid
epitop
vlp
chimer
epitop
peptid
repeatedli
arrang
surfac
vlp
potenti
prospect
peabodi
et
al
proven
numer
experi
insert
foreign
peptid
sequenc
upstream
downstream
viral
structur
protein
gene
littl
effect
assembl
virus
hpv
teunissen
et
al
tissot
et
al
canin
parvoviru
cpv
gilbert
et
al
therefor
insert
foreign
gene
vlp
gene
recombin
technolog
render
vlp
suitabl
antigen
present
tool
hbc
vlp
first
report
vlp
present
exogen
antigen
hbc
protein
dimer
highli
symmetr
rel
stabl
icosahedr
structur
sever
site
exogen
antigen
epitop
incorpor
sequenc
protein
includ
nand
ctermin
major
immunodomin
region
mir
jegerlehn
et
al
except
viral
epitop
vlp
also
present
immunerel
factor
ligand
zhang
et
al
cytotox
cell
epitop
tartour
et
al
well
immunestimul
factor
antimicrobi
peptid
interferon
ifn
proinflammatori
cytokin
chemokin
recogn
pamp
earli
period
innat
immun
liu
et
al
vacher
et
al
tabl
epitop
vector
vlp
present
foreign
antigen
also
selfantigen
sever
vlp
studi
vehicl
use
immun
therapi
especi
therapeut
vaccin
treat
chronic
diseas
cancer
ramqvist
et
al
immunotherapeut
repres
new
promis
class
vaccin
develop
treat
chronic
diseas
fulurija
et
al
rohn
et
al
sonderegg
et
al
spohn
et
al
therapeut
vaccin
demonstr
involv
activ
clearanc
infecti
agent
infect
cell
especi
tumor
cell
break
immun
toler
bypass
mechan
fig
viruslik
particl
vlp
mimic
overal
structur
viru
particl
recogn
readili
immun
system
present
viral
antigen
similar
pathway
authent
conform
induc
strong
immun
respons
diseas
evolv
immun
system
known
lymphocyt
ctl
play
import
role
control
tumor
growth
stimul
specif
ctl
therefor
repres
one
major
goal
design
cancer
vaccin
al
barwani
et
al
speiser
et
al
zamarin
postow
vlp
good
antigen
deliveri
system
effici
introduc
exogen
molecul
mhc
class
pathway
show
import
mediat
antitumor
immun
variou
anim
model
abil
elicit
tumorspecif
ctl
jegerlehn
et
al
addit
vlp
potenti
becom
therapeut
vaccin
treat
chronic
diseas
molecular
clone
technolog
thu
overcom
natur
toler
immun
system
stimul
immun
system
creat
specif
antibodi
toward
selfprotein
spohn
et
al
identif
pathophysiolog
sever
chronic
diseas
key
pathogen
determin
deciph
determinantrel
protein
present
via
vlp
mean
chemic
crosslink
surfac
viruslik
particl
genet
recombin
display
result
specif
autoantibodi
produc
consider
signific
amelior
even
cure
chronic
diseas
tissot
et
al
exampl
avoid
wide
rang
inflammatori
reaction
involv
specif
b
cell
peptid
daefrh
rna
phage
vlp
coval
link
treat
alzheim
diseas
ad
vlp
vaccin
caus
product
antibodi
specif
aforement
strategi
design
vaccin
subject
clinic
trial
chackerian
et
al
wiessner
et
al
vaccin
design
similar
method
specif
nerv
growth
factor
ngf
treat
chronic
pain
rohn
et
al
bacteriophag
vlp
specif
rheumatoid
arthriti
e
triplelay
vlp
assembl
multipl
protein
eg
bluetongu
viru
stewart
et
al
rotaviru
vlp
parez
et
al
envelop
vlp
f
singlelay
vlp
consist
one
protein
eg
influenza
viru
ectodomain
matrix
protein
vlp
g
singlelay
vlp
consist
two
protein
eg
hantavirus
vlp
acuna
et
al
h
twolay
vlp
consist
two
protein
eg
hepat
c
vlp
bellier
klatzmann
twolay
vlp
consist
multipl
protein
eg
sar
coronaviru
vlp
ho
et
al
spohn
et
al
vlp
specif
prevent
hiv
infect
hunter
et
al
anoth
design
strategi
develop
chimer
vlp
vaccin
product
correspond
antibodi
stimul
immunityrel
antigen
present
surfac
vlp
achiev
insert
pathogenrel
gene
express
protein
epitop
particular
viral
structur
protein
ogasawara
et
al
pumpen
gren
yao
et
al
exampl
cuba
et
al
insert
surfac
express
excess
surfac
tumor
cell
siv
gag
gene
produc
chimer
vaccin
suppress
growth
tumor
immun
chimer
vlp
break
toler
selfprotein
gener
specif
cellular
humor
immun
respons
significantli
increas
popul
cell
well
natur
killer
nk
natur
killer
cell
nkt
insid
tumor
tissu
effect
translat
signific
reduct
tumor
growth
cuba
et
al
schiller
et
al
insert
extracellular
loop
zone
chemokin
receptor
mice
bovin
papillomaviru
capsid
protein
produc
autoantibodi
block
step
prevent
hiv
enter
cell
prolifer
cell
chackerian
et
al
approach
also
employ
block
b
cell
toler
autoantigen
treatment
chronic
diseas
eg
rheumatoid
arthriti
osteoporosi
experiment
autoimmun
enceph
system
lupu
erythematosu
myocard
atherosclerosi
hypertens
alzheim
diseas
obes
induc
therapeut
effect
neutral
autoreact
autoantibodi
recogn
potenti
treatment
option
chronic
diseas
chronic
diseas
primarili
caus
multipl
pathogen
factor
make
difficult
cure
nevertheless
therapeut
vaccin
base
vlp
produc
antibodi
aim
autoantigen
zamora
et
al
angiotensin
ii
ang
ii
tissot
et
al
nerv
growth
factor
rohn
et
al
allergen
jegerlehn
et
al
ghrelin
andrad
et
al
help
reduc
risk
cure
certain
diseas
differ
stage
clinic
trial
jen
bachmann
roldao
et
al
ideal
biolog
vector
follow
biolog
characterist
biocompat
solubl
uptak
effici
target
deliveri
high
drug
load
nanoscal
materi
vlp
high
potenti
drug
deliveri
et
al
schott
et
al
tabl
vlp
fit
aforement
demand
certain
degre
among
plenti
studi
first
vlp
easi
produc
largescal
quantiti
use
exist
express
system
either
envelop
nonenvelop
vlp
fig
second
vlp
capabl
target
correspond
cell
transport
surfac
ligand
modif
gene
level
gene
insert
ungaro
et
al
protein
level
chemic
coupl
third
vlp
good
carri
capac
larg
surfac
area
numer
amino
acid
residu
surfac
patel
swartz
fourth
vlp
selfassembl
viral
structur
protein
proper
condit
look
like
protein
cage
larg
caviti
space
encapsul
numer
biolog
molecul
result
expand
molecul
applic
yang
burkhard
final
vlp
thermodynam
stabil
dodecahedr
icosahedr
structur
sum
vlp
emerg
multifunct
platform
system
develop
bioderiv
nanomateri
good
potenti
applic
drug
deliveri
genet
therapi
field
fig
greatest
advers
effect
chemotherapi
cancer
treatment
toxic
normal
tissu
sever
limit
therapeut
effect
anticanc
drug
anticanc
drug
tether
via
amino
acid
residu
surfac
vlp
particularli
icosahedr
vlp
hbv
bacteriophag
bacteriophag
dodecahedr
vlp
adenoviru
ad
vlp
zochowska
et
al
thermodynam
stabil
mild
chemic
coupl
reagent
anticanc
drug
adriamycin
aleomycin
load
onto
surfac
aforement
vlp
hydrazon
bond
creat
amino
acid
residu
addit
anticanc
drug
molecul
also
encapsul
vlp
revers
process
selfassembl
chang
extern
condit
specif
ionic
concentr
huhti
et
al
moreov
vlp
proper
particl
size
good
distribut
biocompat
well
ligand
surfac
invas
special
cell
ligand
bind
receptor
cell
surfac
help
differ
vlp
specif
deliv
drug
variou
target
cell
mimick
nativ
viru
common
ligand
rgd
motif
marelli
et
al
transferrin
singh
et
al
forth
time
anticanc
drug
bioavail
improv
improv
abil
target
transport
accumul
target
cell
therefor
vlp
accept
effect
biolog
vector
carri
drug
studi
highli
infect
virus
without
good
cell
cultur
system
vitro
model
anim
eg
ebola
marburg
virus
human
noroviru
souza
et
al
must
perform
good
experiment
condit
vlp
viru
reserv
conform
viral
capsid
protein
present
ligand
invad
natur
viru
make
vlp
suitabl
surrog
basic
research
biosafeti
level
restrict
virus
therefor
vlp
good
surrog
simul
cell
infect
interact
host
cell
virus
label
vlp
appropri
modif
vlp
surfac
chemic
genet
way
tschern
et
al
far
signific
progress
made
studi
character
virusspecif
surfac
receptor
pathway
viru
entri
mechan
viru
assembl
util
vlp
surrog
mechan
infect
hunov
demonstr
amino
acid
residu
p
domain
protein
respons
specif
receptor
bind
data
come
studi
surrogateshunov
viruslik
particl
vlp
tan
et
al
tan
et
al
tan
jiang
interact
capsid
protein
hev
heparan
sulfat
proteoglycan
hspg
proven
kalia
et
al
research
observ
result
express
hepat
e
viru
capsid
protein
insect
cell
selfassembl
hevlp
vitro
kalia
et
al
observ
process
absorpt
entranc
intracellular
transport
viru
hivvlp
assembl
vitro
jouvenet
et
al
use
green
fluoresc
protein
gfp
gag
major
structur
compon
hivvlp
similar
morpholog
compar
vlp
assembl
gag
protein
jouvenet
et
al
singl
vlp
employ
simul
singl
viru
method
avoid
interfer
caus
intracellular
replic
natur
viru
infect
singl
viru
pokorski
et
al
wei
et
al
aid
advanc
confoc
microscop
goreliket
et
al
observ
cellular
surfac
morpholog
fluoresc
signal
period
viral
entri
singl
polyoma
vlp
techniqu
explain
viral
endocytosi
establish
model
gorelik
et
al
buonaguro
et
al
studi
interact
viru
cellular
receptor
hiv
gagvlp
embed
hiv
envelop
protein
ie
embed
extracellular
function
region
doubletransfect
bacillu
vitro
tschern
et
al
creat
vlp
recombin
express
betalactamas
report
protein
bla
influenza
matrix
vlp
adsorb
target
cell
bla
dissoci
vlp
enter
cell
releas
bla
could
detect
flow
enzymelink
immunosorb
assay
elisa
posit
elisa
could
detect
intracellularli
presenc
antibodi
influenza
viru
bla
enter
cell
likewis
method
employ
detect
ebola
ebov
marburg
marv
virus
vlp
creat
vitro
insert
gfp
protein
ntermin
protein
cpv
vlp
consid
probe
track
interact
cpv
host
cell
morpholog
biophys
antigen
properti
similar
put
virion
vlp
repres
novel
model
studi
virushost
interact
viru
assembl
past
year
vlp
wide
use
biolog
field
vlp
assembl
viral
envelop
glycoprotein
capsid
protein
proven
abil
induc
humor
cellular
immun
respons
experiment
mice
nonprim
even
human
raghunandan
vlp
whatev
form
prophylact
vaccin
recombin
vlp
vaccin
chimer
vlp
vaccin
form
therapeut
vaccin
potenti
use
new
gener
vaccin
candid
variou
viral
infect
guillen
et
al
present
virolog
molecular
biolog
protein
chemistri
inorgan
chemistri
materi
scienc
highli
integr
pursuit
new
materi
control
physic
properti
vlp
shown
amen
chemic
genet
modif
inner
caviti
well
outer
surfac
own
versatil
hierarch
assembl
vlp
provid
new
approach
target
transport
therapeut
drug
biolog
materi
overal
articl
review
develop
current
situat
vlp
vaccin
carrier
therebi
contribut
understand
discoveri
new
biolog
applic
vlp
fig
schemat
represent
assembl
vlp
deriv
envelop
nonenvelop
virus
effici
nanocarri
cargo
deliveri
